spacer
home > ebr > summer 2003 > losing our minds - what the future holds for the treatment of neurodegenerative disorders
PUBLICATIONS
European Biopharmaceutical Review

Losing Our Minds - What the Future Holds for the Treatment of Neurodegenerative Disorders

The words Alzheimer's or Parkinson's can strike terror in anyone's mind, particularly those of us aged over 50. With the average age of the western world's population rising, a disturbing flipside is that an increasing number of those that enter their 60s and beyond are falling victim to neurodegenerative conditions such as Alzheimer's, Parkinson's and stroke. Billions of dollars have been spent on developing novel effective treatments for these conditions with little success. More importantly, treatments that could actually modify the progress of these diseases rather than merely alleviate some of their symptoms, are urgently required. Demand for new and more effective drugs will therefore continue to intensify. Fortunately, there are now signs of light at the end of the tunnel and the near future could see significant progress in the battle to win back our minds.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Itzchak Angel, Vice President Research and Development at D-Pharm Ltd

Dr Angel joined D-Pharm Ltd, a biopharmaceutical company developing lipid-based drugs for the treatment of central nervous system disorders, cancer and autoimmune diseases, as Vice President of Research & Development in 1998.

He obtained his PhD from the University of Hamburg (1982) and did postdoctoral work at the NIH in the US. Formerly, he was Head of the Pharmacology Department at Synthelabo (France). Dr Angel has over 15 years' experience with preclinical and clinical development programmes in a wide range of therapeutic fields.

spacer
Dr Itzchak Angel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm accelerates strategy to broaden service offering into commercial manufacturing

MedPharm Ltd, a leading contract provider of topical and transdermal product design and development services, has announced two new appointments to its Board to support plans to grow its commercial manufacturing services.
More info >>

White Papers

The Importance of Critical Temperatures in the Freeze Drying of Pharmaceutical Products

Biopharma Group

Every formulation has a critical temperature, below which it should be cooled for complete solidification and maintained below during primary drying in order to prevent processing defects. To design a freeze drying cycle on a rational basis such information should be identified.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement